The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibe

References

• Garber AM, Sox Jr HC, Littenberg B. Screening asymptomatic adults for cardiac risk factors: the serum cholesterol level. Ann Intern Med 1989;110:622–39
   PubMed Web of Science ®Google Scholar
• Hancock EW. 1 Cardiovascular medicine: VIII coronary artery disease – epidemiology and prevention. In: Rubenstein E, Federman DD, editors. Scientific American Medicine. New York: Scientific American, Inc.; 1991
   Google Scholar
• Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? JAMA 1986;256:2823–8
   Google Scholar
• Steinberg D, Witztum JL. Lipoproteins and atherogenesis: current concepts. JAMA 1990;264:3047–52
   PubMed Web of Science ®Google Scholar
• van Heek M, France CF, McLeod RL, et al. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH 58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH 48461. J Pharmacol Exp Ther 1997;283:157–63
   PubMed Web of Science ®Google Scholar
• van Heek M, Farley C, Compton DS, et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol 2000;129:1748–54
   PubMed Web of Science ®Google Scholar
• Altmann SW, Davis HR, Zhu LJ, et al. Niemann–Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science 2004;303:1201–4
   PubMed Web of Science ®Google Scholar
• Sudhop T, Lütjohann D, Kodal A, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002;106:1943–8
   PubMed Web of Science ®Google Scholar
• Patrick JE, Kosoglou T, Stauber KL, et al. Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. Drug Metabol Dispos 2002;30:430–7
   PubMed Web of Science ®Google Scholar
• Knopp RH, Gitter H, Truitt T, et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003;24:729–41
   PubMed Web of Science ®Google Scholar
• Bayes HE, Moore PB, Drehobl MA, et al. Ezetimibe Study Group. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther 2001;23:1209–30
   Google Scholar
• Dujovne CA, Ettinger MP, McNeer JF, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1092–7
   PubMed Web of Science ®Google Scholar
• Knopp RH, Dujovne CA, LeBeaut A, et al. Ezetimibe Study Group. Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolemia: a pooled analysis from two controlled phase II clinical studies. Int J Clin Pract 2003;57:363–8
   Google Scholar
• Langtry HD, Markham A. Fluvastatin: a review of its use in lipid disorders. Drugs 1999;57:583–606
   PubMed Web of Science ®Google Scholar
• Davis HR, Pula KK, Alton KB, et al. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methyl glutaryl coenzyme a reductase inhibitors in dogs. Metabolism, 2001;50:1234–41
   PubMed Web of Science ®Google Scholar
• Kosoglou T, Meyer I, Veltri EP, et al. Pharmacodynamic interaction between the new cholesterol absorption inhibitor ezetimibe and simvastatin. Br J Clin Pharmacol 2002;54:309–19
   PubMed Web of Science ®Google Scholar
• Gibaldi M, Perrier D. Pharmacokinetics, 2nd edn., New York: Marcel Dekker, Inc.; 1982, pp.409–17
   Google Scholar
• Kosoglou T, Statkevich P, Meyer I, et al. Effects of ezetimibe on the pharmacodynamics and pharmacokinetics of lovastatin. Curr Med Res Opin 2004;20:955–65
   PubMed Web of Science ®Google Scholar
• Lescol® (fluvastatin) SPC. Novartis Pharmaceuticals UK Ltd. April 2004. Available from electronic Medicine Compendium at http://emc.medicines.org.uk/emc/assets/c/html/displaydoc. asp?documentid=1292
   Google Scholar
• Fischer V, Johanson L, Heitz F, et al. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metabol Disp 1999;27:410–16
   PubMed Web of Science ®Google Scholar
• Zhu Y, Statkevich P, Kosoglou T, et al. Effect of ezetimibe (SCH 58235) on the activity of drug metabolizing enzymes in vivo. Clin Pharmacol Ther 2000;67:152 [abstract]
   Google Scholar
• Statkevich, P., Reyderman, L., Kosoglou, T., et al. Ezetimibe does not affect the pharmacokinetics and pharmacodynamics of glipizide. Clin Pharmacol Ther 2001;69:P67 [abstract]
   Google Scholar
• Bauer KS, Statkevich P, Kosoglou T, et al. Ezetimibe (SCH 58235) does not affect the pharmacokinetics and pharmacodynamics of warfarin. Clin Pharmacol Ther 2001;69:P5 [abstract]
   Google Scholar
• Zhu Y, Statkevich P, Kosoglou T, et al. Lack of a pharmacokinetic interaction between ezetimibe and atorvastatin. Clin Pharmacol Ther 2001;69:P68 [abstract]
   Google Scholar
• Reyderman L, Kosoglou T, Boutros T, et al. Pharmacokinetic interaction between ezetimibe and lovastatin in healthy volunteers. Curr Med Res Opin 2004;20:1493–1500
   PubMed Web of Science ®Google Scholar
• Kosoglou T, Meyer I, Veltri EP, et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br J Clin Pharmacol 2002;54:309–19
   PubMed Web of Science ®Google Scholar
• Keung ACF, Kosoglou T, Statkevich P, et al. Ezetimibe does not affect the pharmacokinetics of oral contraceptives. Clin Pharmacol Ther 2001;69:P55 [abstract]
   Google Scholar
• Ezetrol® (ezetimibe) 10 mg Tablets SPC. MSD-SP Ltd. October 2004. Available from electronic Medicine Compendium at http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=12091
   Google Scholar